Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate

Atherosclerosis. 1990 Oct;84(2-3):213-7. doi: 10.1016/0021-9150(90)90093-x.


The effect of low dose (600 mg/day) alpha-tocopheryl nicotinate on serum lipoprotein(a) (Lp(a] concentration was studied in 28 hyperlipidaemic patients. Serum lipids, lipoproteins and apolipoproteins, except for Lp(a), tended to increase after treatment. In particular, the changes in HDL-cholesterol and apo C-II levels were statistically significant. On the other hand, serum Lp(a) levels in all patients decreased significantly after 2 months of treatment. Furthermore, no difference between before and after treatment was observed in the group with initial Lp(a) levels less than 18 mg/dl, whereas Lp(a) concentrations decreased significantly after treatment in the group with levels greater than or equal to 18 mg/dl. The effects of probucol and alpha-tocopheryl nicotinate on serum Lp(a), total cholesterol and HDL-cholesterol were entirely different. Possible mechanisms of alpha-tocopheryl nicotinate on serum Lp(a) and lipoprotein metabolism are discussed.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Apolipoprotein C-II
  • Apolipoproteins C / blood
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Female
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy*
  • Lipoprotein(a)
  • Lipoproteins / blood*
  • Male
  • Middle Aged
  • Nicotinic Acids / therapeutic use*
  • Probucol / therapeutic use
  • Vitamin E / analogs & derivatives*
  • Vitamin E / therapeutic use


  • Apolipoprotein C-II
  • Apolipoproteins C
  • Cholesterol, HDL
  • Lipoprotein(a)
  • Lipoproteins
  • Nicotinic Acids
  • Vitamin E
  • alpha-tocopheryl nicotinate
  • Cholesterol
  • Probucol